文献速递儿童青少年精神心境障碍

重复低剂量麦角酸二乙酰胺治疗成人注意缺陷多动障碍的安全性与疗效:一项随机临床试验

Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

这项为期6周的多中心、双盲、安慰剂对照、平行组2A期随机临床试验纳入53例18至65岁中重度症状的成人注意缺陷多动障碍(ADHD)患者,比较每周两次麦角酸二乙酰胺(LSD)20 μg与安慰剂共6周(12次)的效果。LSD组AISRS评分平均改善-7.1分(95%CI,-10.1至-4.0),安慰剂组平均改善-8.9分(95%CI,-12.0至-5.8),组间无差异。LSD在门诊环境下身体安全且心理耐受性总体良好,但在减少ADHD症状方面并不优于安慰剂。

要点

  • LSD组AISRS平均改善-7.1分(95%CI,-10.1至-4.0),安慰剂组-8.9分(95%CI,-12.0至-5.8),组间无差异。
  • LSD在门诊环境下身体安全且心理耐受性总体良好。
  • 重复低剂量LSD在减少ADHD症状方面不优于安慰剂。

核心结论

  • 在这项随机临床试验中,重复低剂量LSD在门诊环境下给药是安全的,但在减少ADHD症状方面并不比安慰剂更有效。

研究设计与样本

  • 这是一项为期6周的多中心、双盲、安慰剂对照、平行组2A期随机临床试验,于2021年12月17日至2023年12月4日进行,数据分析时间为2024年3月22日至2024年8月19日。
  • 门诊治疗在2个中心提供:瑞士巴塞尔的大学医院和荷兰马斯特里赫特大学。
  • 纳入18至65岁、既往诊断为ADHD且症状为中重度(AISRS评分≥26且临床总体印象严重度量表评分≥4)的成人;关键排除标准包括当前患有某些重大精神或躯体疾病以及使用可能相互作用的药物。
  • 共53名参与者被随机分配至LSD组(n=27)或安慰剂组(n=26);参与者平均(SD)年龄为37(12)岁,22名参与者(42%)为女性。
  • 参与者接受LSD(20 μg)或安慰剂,每周两次,持续6周(共12次给药)。

主要发现

  • 主要结局为从基线至第6周ADHD症状的变化,采用AISRS评估,并使用重复测量混合效应模型分析。
  • LSD组AISRS评分平均改善-7.1分(95%CI,-10.1至-4.0)。
  • 安慰剂组AISRS评分平均改善-8.9分(95%CI,-12.0至-5.8),组间无差异。
  • LSD在身体上安全,心理上总体耐受良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Microdosing psychedelics, including lysergic acid diethylamide (LSD), has gained attention for its potential benefits in several psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD). However, LSD's efficacy in reducing ADHD symptoms remains unknown. OBJECTIVE: To determine the safety and efficacy of repeated low doses of LSD in reducing ADHD symptoms compared with placebo. DESIGN, SETTING, AND PARTICIPANTS: This was a 6-week, multicenter, double-blind, placebo-controlled, parallel-group phase 2A randomized clinical trial conducted between December 17, 2021, and December 4, 2023. Data were analyzed from March 22, 2024, to August 19, 2024. Outpatient treatment was provided at 2 centers: University Hospital in Basel, Switzerland, and Maastricht University in the Netherlands. Adults aged 18 to 65 years with a prior ADHD diagnosis who presented with moderate to severe symptoms (Adult Investigator Symptom Rating Scale [AISRS] score ≥26 and Clinical Global Impression Severity score ≥4) were eligible for inclusion. Key exclusion criteria included selected current major psychiatric or somatic disorders and the use of potentially interacting medications. INTERVENTION: Participants received either LSD (20 μg) or placebo twice weekly for 6 weeks (total of 12 doses). MAIN OUTCOME AND MEASURES: The primary outcome was the change in ADHD symptoms from baseline to week 6, assessed by the AISRS and analyzed with a mixed-effects model for repeated measures. RESULTS: A total of 53 participants were randomized to LSD (n = 27) or placebo (n = 26). Mean (SD) participant age was 37 (12) years, and 22 participants (42%) were female. The LSD group presented a mean AISRS improvement of -7.1 points (95% CI, -10.1 to -4.0). The placebo group presented a mean AISRS improvement of -8.9 points (95% CI, -12.0 to -5.8), with no difference between groups. LSD was physically safe and psychologically well tolerated overall. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, repeated low-dose LSD administration was safe in an outpatient setting, but it was not more efficacious than placebo in reducing ADHD symptoms. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05200936.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Mueller L, Santos de Jesus J, Schmid Y, et al. Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 40105807. doi:10.1001/jamapsychiatry.2025.0044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。